Design, synthesis, and structure - Activity relationship of tropane muscarinic acetylcholine receptor antagonists

Journal of Medicinal Chemistry

Volumn 52, Issue 16, 2009, Pages 5241-5252

  Lainé, Dramane I ^a   Wan, Zehong ^a   Yan, Hongxing ^a   Zhu, Chongjie ^a   Xie, Haibo ^a   Fu, Wei ^a   Busch Petersen, Jakob ^a   Neipp, Christopher ^a   Davis, Roderick ^a   Widdowson, Katherine L ^a   Blaney, Frank E ^a   Foley, James ^a   Bacon, Alicia M ^a   Webb, Edward F ^a   Luttmann, Mark A ^a   Burman, Miriam ^a   Sarau, Henry M ^a   Salmon, Michael ^a   Palovich, Michael R ^a   Belmonte, Kristen ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 ENDO) 1,1 BIS (3 FLUOROPHENYL) 2 (8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCT 3 YL)ETHANOL IODIDE; (3 ENDO) 1,1 BIS(3 FLUORO 2 METHYLPHENYL) 2 (8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCT 3 YL)ETHANOL BROMIDE; (3 ENDO) 1,1 BIS(3 THIENYL) 2 (8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCT 3 YL)ETHANOL IODIDE; (3 ENDO) 1,1 BIS(3,4 DIFLUOROPHENYL) 2 (8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCT 3 YL)ETHANOL BROMIDE; (3 ENDO) 1,1 BIS(4 CHLOROPHENYL) 2 (8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCT 3 YL)ETHANOL IODIDE; (3 ENDO) 1,1 BIS(5 FLUORO 2 METHYLPHENYL) 2 (8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCT 3 YL)ETHANOL BROMIDE; (3 ENDO) 3 (2 CYANO 2,2 DIPHENYLETHYL) 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE BROMIDE; (3 ENDO) 3 (2 HYDROXY 2,2 DI 2 THIENYLETHYL) 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE IODIDE; (3 ENDO) 3 (2 HYDROXY 2,2 DI 2 THIENYLETHYL) 9,9 DIMETHYL 9 AZONIABICYCLO[3.3.1]NONANE IODIDE; (3 ENDO) 3 (2 HYDROXY 2,2 DIPHENYLETHYL) 9,9 DIMETHYL 9 AZONIABICYCLO[3.3.1]NONANE BROMIDE; (3 ENDO) 3 (2,2 DI 2 THIENYLETHENYL) 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE BROMIDE; (3 ENDO) 3 (2,2 DI 2 THIENYLETHENYL) 9,9 DIMETHYL 9 AZONIABICYCLO[3.3.1]NONANE BROMIDE; (3 ENDO) 3 [2 HYDROXY 2,2 BIS(2 METHYLPHENYL)ETHYL] 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE BROMIDE; (3 ENDO) 3 [2 HYDROXY 2,2 BIS(2 METHYLPHENYL)ETHYL] 9,9 DIMETHYL 9 AZONIABICYCLO[3.3.1]NONANE IODIDE; (3 ENDO) 3 [2 HYDROXY 2,2 BIS(4 METHYL 3 THIENYL)ETHYL] 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE BROMIDE; (3 ENDO) 3 [2 HYDROXY 2,2 BIS[2 (METHYLOXY)PHENYL]ETHYL] 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE BROMIDE; (3 ENDO) 3 [2 HYDROXY 2,2 BIS[4 (METHYLOXY)PHENYL]ETHYL] 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE IODIDE; (3 ENDO) 3 [2,2 BIS(2 METHYLPHENYL)ETHENYL] 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE BROMIDE; (3 ENDO) 3 [2,2 BIS(3 CHLOROPHENYL) 2 HYDROXYETHYL] 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE IODIDE; (3 ENDO) 3 [2,2 BIS(3,5 DIFLUOROPHENYL) 2 HYDROXYETHYL] 8,8 DIMETHYL 8 AZONIABICYCLO[3.2.1]OCTANE BROMIDE; 3 [(3 ENDO) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 3 YL] 2,2 DIPHENYLPROPANAMIDE TRIFLUOROACETATE; 3 [(3 ENDO) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 3 YL] 2,2 DIPHENYLPROPANENITRILE TRIFLUOROACETATE; MUSCARINIC RECEPTOR BLOCKING AGENT; N [3 [(3 ENDO) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 3 YL] 2,2 DIPHENYLPROPYL] N' (PHENYLMETHYL)UREA TRIFLUOROACETATE; N [3 [(3 ENDO) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 3 YL] 2,2 DIPHENYLPROPYL]ACETAMIDE TRIFLUOROACETATE; N [3 [(3 ENDO) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 3 YL] 2,2 DIPHENYLPROPYL]BENZENESULFONAMIDE TRIFLUOROACETATE; N [3 [(3 ENDO) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 3 YL] 2,2 DIPHENYLPROPYL]METHANESULFONAMIDE TRIFLUOROACETATE; N ETHYL N [3 [(3 ENDO) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 3 YL] 2,2 DIPHENYLPROPYL]UREA TRIFLUOROACETATE; TROPANE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRONCHOSPASM; CONFORMATIONAL TRANSITION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG IDENTIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG SYNTHESIS; EXPERIMENTAL MODEL; HUMAN; HUMAN TISSUE; IC 50; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; BIOLOGICAL AVAILABILITY; BIPHENYL COMPOUNDS; BRONCHI; BRONCHOCONSTRICTION; CALCIUM; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; MICE; MICE, INBRED BALB C; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; RADIOLIGAND ASSAY; RATS; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; RECEPTOR, MUSCARINIC M3; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TROPANES;

EID: 69049086656     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900736e     Document Type: Article

References (29)

1. Caulfield, M. P.; Birdsall, N. J. M. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol. Rev. 1998, 50, 279-290.
2. Eglen, R. M. Muscarinic receptor subtype pharmacology and physiology. Prog. Med. Chem. 2005, 43, 105-136.
3. Caulfield, M. P. Muscarinic receptors. Characterization, coupling and function. Pharmacol. Ther. 1993, 58, 319-359.
4. Lee, A. M.; Jacoby, D. B.; Fryer, A. D. Selective muscarinic receptor antagonists for airway diseases. Cur. Opin. Pharmacol. 2001, 1, 223-229.
5. Barnes, P. J. Muscarinic receptor subtypes: implications for lung disease. Thorax 1989, 44, 161-167.
6. Gater, P. J.; Alabastar, V. J.; Piper, I. A study of the muscarinic receptor subtype mediating secretion in the cat trachea in vitro. Pulm. Pharmacol. 1989, 2, 87-92.
7. Faulkner, D.; Fryer, A. D.; MacLagan, J. Postganglionic muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br. J. Pharmacol. 1986, 88, 181-187.
8. Lammers, J.-W. J.; Minette, P.; McCusker, M.; Barnes, P. J. The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in Humans. Am. Rev. Respir. Dis. 1989, 139, 446-449.
9. Hay, D. W. P. Chronic obstructive pulmonary disease: emerging therapies. Curr. Opin. Chem. Biol. 2000, 4, 412-419.
10. Fryer, A. D.; Adamko, D. J.; Yost, B. L.; Jacoby, D. B. Effects of inflammatory cells on neuronalM2 muscarinic receptor function in the lung. Life Sci. 1999, 64, 449-455.
11. Gross, J. N. Anticholinergic agents in asthma and COPD. Eur. J. Pharmacol. 2006, 533, 36-39.
12. ZuWallack, A. R.; ZuWallack, R. L. Tiotropium bromide, a new, once-daily inhaled anticholinergic bronchodilator for chronic obstructive pulmonary disease. Expert Opin. Pharmacother. 2004, 5, 1827-1835.
13. Gyermek, L. Pharmacology of Anti-Muscarinic Agents; CRC: Boca Raton, FL, 1997; pp 267-277.
14. Pedretti, A.; Vistoli, G.; Marconi, C.; Testa, B. Muscarinic receptors: a comparative analysis of structural features and binding modes through homology modeling and molecular docking. Chem. Biodiversity 2006, 3, 481-501.
15. Innes, I. R.; Nickerson, M. Atropine, Scopolamine and Related Antimuscarinic Drugs. In The Pharmacological Basis of Therapeutics, 5th ed.; Goodman, L. S., Gilman, A. G., Eds.; Macmillan Publishing Co.: New York, 1975; pp 514-532.
16. Gordon, R. K.; Breuer, E.; Padilla, F. N.; Ruthman, M. S.; Chaing, P. K. Distance geometry of a-substituted 2,2-diphenylpropionate antimuscarinic. Mol. Pharmacol. 1989, 36, 766-772.
17. Zirkle, C. L.; Anderson, E. L.; Craig, P. N.; Gerns, F. R.; Indik, Z. K.; Pavloff, A. M. 3-substituted tropane derivatives. III. 3-Substituted tropane carbinols, alkenes, and alkanes. J. Med. Pharm. Chem. 1962, 5, 341-356.
18. Maryanoff, B. E.; Reitz, A. B. The Wittig olefination reaction and modification involving phosphoryl-stabilized carbanions. Stereochemistry, mechanisms and selected synthetic aspects. Chem. Rev. 1989, 89, 863-927.
19. Tavasli, M.; O'Hagan, D.; Batsanov, A. S.; Foxon, G. R.; Halliwell, R. F.; Howard, J. A. K. The synthesis, conformation and antimuscarinic properties of ketone analogues of tropane esters. J. Chem. Soc., Perkin Trans. 1 1999, 3455-3461.
20. Bradley, A. L.; Izenwasser, S.; Wade, D.; Cararas, S.; Trudell, M. L. Synthesis of dopamine transporter selective 3-{2-diarylmethoxyethylidene)}-8- alkylaryl-8-azabicyclo[3.2.1]octanes. Bioorg. Med. Chem. Let. 2003, 13, 629-632.
21. Zhang, Y.; Joseph, D. B.; Bowen, W. D.; Flippen-Anderson, J. L.; Dersch, C. M.; Rothman, R. B.; Jacobson, A. E.; Rice, K. C. Synthesis and biological evaluation of tropane-like 1-{2-bis(4-fluorophenyl)methoxy]ethyl}-4-(3- phenylpropyl)piperazine (GBR12909) analogues. J. Med. Chem. 2001, 44, 3937-3945.
22. Jones, G. Knoevenagel condensation. Org. React. 1967, 15, 204-599.
23. Zirkle, C. L. Tertiary Alcohol Derivatives of 8-Alkyl-nortropanes and the Acid and Quaternary Ammonium Salts Thereof. US2,800,481, July 23, 1957.
24. Zirkle, C. L.; Geissman, T. A.; Bloom, M.; Craig, P. N.; Gerns, F. R.; Indik, Z. K.; Pavloff, A. M. 3-Substituted tropane derivatives. I. The synthesis and stereochemistry of the tropane-3-carboxylic acids and their esters. A comparison of positional isomers in the tropane series. J. Org. Chem. 1962, 27, 1269-1279.
25. Takahashi, Y.; Yoneda, N.; Nagai, H. Carboxylation of alcohols with carbon monoxide supersaturated in strong acid. Facile synthesis of 2,2-bis(4-halophenyl)acetic, -propionic, and related acids. Chem. Lett. 1985, 11, 1733-1734.
26. Arunlakshana, O.; Schild, H. O. Some quantitative uses of drug antagonists. Br. J. Pharmacol. 1959, 14, 48-58.
27. Hamelmann, E.; Schwarze, J.; Takeda, K.; Oshiba, A.; Gelfand, E. W. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am. J. Respir. Crit. Care Med. 1997, 156, 766-775.
28. Tayab, Z. R.; Hochhaus, G. Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems. Expert Opin. Drug Delivery 2005, 2, 519-532.
29. Leusch, A.; Eichhorn, B.; Muller, G.; Rominger, K.-L. Pharmacokinetics and tissue ditribution of the anticholinergics tiotropium and ipratropium in the rat and dog. Biopharm. Drug Dispos. 2001, 22, 199-212.